Pharma shares in focus; Sun Pharma gains 4% in intra-day deals
Sun Pharma, Unichem Lab, Ipca Lab, Wockhardt, Marksans Pharma, Cadila Healthcare and Aurobindo Pharma were up in the range of 3% to 8%
 "Pharma shares in focus; Sun Pharma gains 4% in intra-day deals")
premium
Shares of pharmaceutical companies were in focus, trading higher by up to 7% on the bourses in otherwise range-bound market. Sun Pharmaceutical Industries, Unichem Laboratories, Ipca Laboratories, Wockhardt, Marksans Pharma, Cadila Healthcare and Aurobindo Pharma were up in the range of 3% to 8%.
At 12:18 PM; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.6% as compared to 0.02% decline in the Nifty 50 index. The S&P BSE Healthcare index too up 2% against 0.22% rise in the S&P BSE Sensex.
Sun Pharma was up 4.5% to Rs 555 in intra-day trade, extending its Thursday’s 1.5% gain on the BSE, after the company said its subsidiary has received approval from the US health regulator to market generic version of GSK's Coreg CR, extended release capsules in the American market.
Meanwhile, Indian pharmaceutical companies are expected to post better results in the second quarter as compared to the first quarter of the current fiscal, following recovery in the domestic business and several launches in the US market, a report says.
“Pharma companies would report a sequential respite in earnings as domestic business stages a rebound after Goods and Service Tax (GST)-led woes dampened what was already a bruising US operating environment in the previous quarter. YoY we still expect pain to linger as an elevated 10-12% price erosion and high base of F17 lead to unfavourable comparison,” analyst at IIFL Wealth Management said in Q2FY18 result preview.
“The pharmaceutical companies under our coverage universe are expected to report a muted performance on YoY basis in Q2FY18 due to multiple headwinds in the US led by increasing pricing pressure, lack of niche opportunities and channel consolidation. However, we see sequential improvement on account of lower base and rebound in domestic formulation business,” the brokerage firm Reliance Securities said in results preview.
Domestic formulation business of these companies was adversely impacted in 1QFY18 on the back of challenges relating to GST (inventory de-stocking by trade channels in run-up to roll-out). However, we expect Q2FY18 to be stronger than Q1FY18 owing to inventory re-stocking at retailers’ level, added report.
“Sequentially earnings will benefit from rebound in India business post the slump in Q1FY18; and sales of gLialda (Cadila Healthcare), gRenvela (Aurobindo Pharma) and gVytorin (Dr Reddy’s Laboratories), although impact due to end of gTamiflu, gZetia and competition in gGlumetza (LPC) is anticipated,” according to analysts at Edelweiss Securities.
At 12:18 PM; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.6% as compared to 0.02% decline in the Nifty 50 index. The S&P BSE Healthcare index too up 2% against 0.22% rise in the S&P BSE Sensex.
Sun Pharma was up 4.5% to Rs 555 in intra-day trade, extending its Thursday’s 1.5% gain on the BSE, after the company said its subsidiary has received approval from the US health regulator to market generic version of GSK's Coreg CR, extended release capsules in the American market.
Meanwhile, Indian pharmaceutical companies are expected to post better results in the second quarter as compared to the first quarter of the current fiscal, following recovery in the domestic business and several launches in the US market, a report says.
“Pharma companies would report a sequential respite in earnings as domestic business stages a rebound after Goods and Service Tax (GST)-led woes dampened what was already a bruising US operating environment in the previous quarter. YoY we still expect pain to linger as an elevated 10-12% price erosion and high base of F17 lead to unfavourable comparison,” analyst at IIFL Wealth Management said in Q2FY18 result preview.
“The pharmaceutical companies under our coverage universe are expected to report a muted performance on YoY basis in Q2FY18 due to multiple headwinds in the US led by increasing pricing pressure, lack of niche opportunities and channel consolidation. However, we see sequential improvement on account of lower base and rebound in domestic formulation business,” the brokerage firm Reliance Securities said in results preview.
Domestic formulation business of these companies was adversely impacted in 1QFY18 on the back of challenges relating to GST (inventory de-stocking by trade channels in run-up to roll-out). However, we expect Q2FY18 to be stronger than Q1FY18 owing to inventory re-stocking at retailers’ level, added report.
“Sequentially earnings will benefit from rebound in India business post the slump in Q1FY18; and sales of gLialda (Cadila Healthcare), gRenvela (Aurobindo Pharma) and gVytorin (Dr Reddy’s Laboratories), although impact due to end of gTamiflu, gZetia and competition in gGlumetza (LPC) is anticipated,” according to analysts at Edelweiss Securities.
| COMPANY | LATEST | PREV CLOSE | GAIN(%) |
| IPCA LABS. | 539.0 | 503.7 | 7.02 |
| UNICHEM LABS. | 306.0 | 287.0 | 6.64 |
| WOCKHARDT | 659.0 | 626.5 | 5.19 |
| SUN PHARMA.INDS. | 549.4 | 531.0 | 3.47 |
| MARKSANS PHARMA | 44.5 | 43.2 | 3.13 |
| J B CHEM & PHARM | 284.1 | 276.1 | 2.92 |
| AJANTA PHARMA | 1201.8 | 1168.8 | 2.82 |
| CADILA HEALTH. | 496.1 | 483.2 | 2.67 |
| AUROBINDO PHARMA | 769.0 | 749.8 | 2.57 |
| DIVI'S LAB. | 881.3 | 859.6 | 2.52 |
| JUBILANT LIFE | 647.0 | 631.4 | 2.48 |
| STRIDES SHASUN | 855.0 | 835.7 | 2.32 |
| GLENMARK PHARMA. | 611.5 | 599.5 | 2.00 |
| LUPIN | 1016.5 | 997.1 | 1.95 |
| DR REDDY'S LABS | 2389.8 | 2345.7 | 1.88 |
| CIPLA | 623.8 | 612.4 | 1.86 |
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%